title: A lower dose threshold for the in vivo protective adaptive response to radiation. Tumorigenesis in chronically exposed normal and Trp53 heterozygous C57BL/6 mice.
abstract: Low doses of ionizing radiation to cells and animals may induce adaptive responses that reduce the risk of cancer. However, there are upper dose thresholds above which these protective adaptive responses do not occur. We have now tested the hypothesis that there are similar lower dose thresholds that must be exceeded to induce protective effects in vivo. We examined the effects of low-dose/low-dose-rate fractionated exposures on cancer formation in Trp53 normal or cancer-prone Trp53 heterozygous female C57BL/6 mice. Beginning at 6 weeks of age, mice were exposed 5 days/week to single daily doses (0.33 mGy, 0.7 mGy/h) totaling 48, 97 or 146 mGy over 30, 60 or 90 weeks. The exposures for shorter times (up to 60 weeks) appeared to be below the level necessary to induce overall protective adaptive responses in Trp53 normal mice, and detrimental effects (shortened life span, increased frequency) evident for only specific tumor types (B- and T-cell lymphomas) were produced. Only when the exposures were continued for 90 weeks did the dose become sufficient to induce protective adaptive responses, balancing the detrimental effects for these specific cancers and reducing the risk level back to that of the unexposed animals. Detrimental effects were not seen for other tumor types, and a protective effect was seen for sarcomas after 60 weeks of exposure, which was then lost when the exposure continued for 90 weeks. As shown previously for the upper dose threshold for protection by low doses, the lower dose boundary between protection and harm was influenced by Trp53 functionality. Neither protection nor harm was observed in exposed Trp53 heterozygous mice, indicating that reduced Trp53 function raises the lower dose/ dose-rate threshold for both detrimental and protective tumorigenic effects.
authors.affiliation: Radiation Biology and Health Physics Branch, Atomic Energy of Canada, Ontario, Canada. mitchelr@aecl.ca
authors.forename: R E J
authors.initials: RE
authors.lastname: Mitchel
authors.forename: P
authors.initials: P
authors.lastname: Burchart
authors.forename: H
authors.initials: H
authors.lastname: Wyatt
mesh_terms: D000818:Animals; D016022:Case-Control Studies; D004781:Environmental Exposure; D005260:Female; D006579:Heterozygote; D016393:Lymphoma, B-Cell / Q000209:etiology; D016399:Lymphoma, T-Cell / Q000209:etiology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009369:Neoplasms / Q000209:etiology* / Q000378:metabolism* / Q000473:pathology; D011829:Radiation Dosage; D012306:Risk; D015996:Survival Rate; D013997:Time Factors; D016159:Tumor Suppressor Protein p53 / Q000172:deficiency / Q000235:genetics* / Q000378:metabolism*
chemical_list: D016159:Tumor Suppressor Protein p53